Treatment with sodium oxybate in children with type 1 narcolepsy (NT1) is associated with weight reduction that stabilizes after 2 years of therapy, according to study results published in Sleep.

Overweight and obesity are common in children with NT1, exposing the patients to increased risk for cardiovascular complications and reduced quality of life. Previous studies reported that treatment with sodium oxybate in adults with NT1 is associated with a weight decrease. As limited data exist on the effect of sodium oxybate on weight in children, the objective of the current study was to determine its impact on body mass index (BMI) in pediatric NT1.

This retrospective study included 129 NT1 patients (26.4% obese; 29.5% overweight).  Of these, 50 patients (mean age, 12 years; 52% girls; mean BMI z-score, 1.2) received sodium oxybate as monotherapy, 30 patients (mean age, 12.3 years; 50% girls; mean BMI z-score 1.4) were treated with sodium oxybate in combination with additional therapy, and 49 patients (mean age, 11.7 years; 42.9% girls; mean BMI z-score 0.7) were not treated with sodium oxybate.

At 1 year, a significant BMI z-score reduction was documented among patients treated with sodium oxybate as monotherapy (mean BMI z-score 0.4; P <.001) or in combination with other therapies (mean BMI z-score 1.0; P =.002). At 2 years, a significant BMI-z score reduction was reported only among patients in the combination therapy group (from 1.0 to 0.6, P =.037). Weight stabilized after 2 years of sodium oxybate therapy.


Continue Reading

The adjusted beta coefficients of sodium oxybate monotherapy compared with other therapies was -0.82 (95% CI, -1.14 to -0.51; P <.001) and beta coefficients of sodium oxybate as part of a combination therapy compared with other therapies was -0.56 (95% CI,-0.92 to -0.19; P =.003).

On the other hand, in children not treated with sodium oxybate, a significant weight increase was reported during the follow-up period, specifically between years 2 and 3 of therapy (BMI z-score value increased from 0.3 to 0.5; P =.037).

The study had several limitations, including the retrospective design, loss of patients during follow-up, and lacking data regarding efficacy on NT1 symptoms and adverse reactions to treatments.

“SO [sodium oxybate] was associated with a significant weight loss in the first year of treatment in a retrospective cohort of consecutive NT1 children and adolescents, an effect that may be considered favourable, and not adverse, given the dramatic comorbidity of overweight / obesity in NT1 in particular in childhood,” concluded the study researchers.

Reference

Ponziani V, Pizza F, Zenesini C, Vignatelli L, Pession A, Plazzi G. BMI changes in paediatric type 1 narcolepsy under sodium oxybate treatment. Sleep. Published online January 3, 2021. doi:10.1093/sleep/zsaa295

This article originally appeared on Neurology Advisor